Cited by 885Genetic Neurodegenerative DiseasesMetabolism and Genetic DisordersMitochondrial Function and Pathology

The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Browne, Susan E., Bowling, Allen C., Macgarvey, Usha, Baik, M. Jay, Berger, Stephanie C., Muquit, Miratul M. K., Bird, Edward D., Beal, M. Flint·1997·Annals of Neurology

DOI 10.1002/ana.410410514

Open this paper in CoChat — free account

Abstract

The etiology of the selective neuronal death that occurs in Huntington's disease (HD) is unknown. Several lines of evidence implicate the involvement of energetic defects and oxidative damage in the disease process, including a recent study that demonstrated an interaction between huntingtin protein and the glycolytic enzyme glyceraldehyde‐3‐phosphate dehydrogenase (GAPDH). Using spectrophotometric assays in postmortem brain tissue, we found evidence of impaired oxidative phosphorylation enzyme activities restricted to the basal ganglia in HD brain, while enzyme activities were unaltered in three regions relatively spared by HD pathology (frontal cortex, parietal cortex, and cerebellum). Citrate synthase‐corrected complex II‐III activity was markedly reduced in both HD caudate (−29%) and putamen (−67%), and complex IV activity was reduced in HD putamen (−62%). Complex I and GAPDH activities were unaltered in all regions examined. We also measured levels of the oxidative damage product 8‐hydroxydeoxyguanosine (OH 8 dG) in nuclear DNA, and superoxide dismutase (SOD) activity. OH 8 dG levels were significantly increased in HD caudate. Cytosolic SOD activity was slightly reduced in HD parietal cortex and cerebellum, whereas particulate SOD activity was unaltered in these regions. These results further support a role for metabolic dysfunction and oxidative damage in the pathogenesis of HD.

Integrity signals

Registry

Crossref · 10.1002/ana.410410514

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
Bradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Self-citation
Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses?
Beal, M. F. (1992) · Annals of Neurology · doi:10.1002/ana.410310202 · Cited by 962
Self-citation
Glutamate becomes neurotoxic via the N-methyl-d-aspartate receptor when intracellular energy levels are reduced
Novelli, A., Reilly, J. A., Lysko, P. G., & Henneberry, R. C. (1988) · Brain Research · doi:10.1016/0006-8993(88)90765-2 · Cited by 961
Mitochondrial defect in Huntington's disease caudate nucleus
Gu, M., Gash, M. T., Mann, V. M., Javoy‐Agid, F., Cooper, J. M., & Schapira, A. H. V. (1996) · Annals of Neurology · doi:10.1002/ana.410390317 · Cited by 758
Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain
Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., & Beal, M. F. (1993) · Annals of Neurology · doi:10.1002/ana.410340416 · Cited by 757
Self-citation
Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons
DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., Vonsattel, J.-P., Carraway, R., Reeves, S. A., et al. (1995) · Neuron · doi:10.1016/0896-6273(95)90346-1 · Cited by 749
Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency
Bourgeron, T., Rustin, P., Chretien, D., Birch-Machin, M., Bourgeois, M., Viegas-Péquignot, E., Munnich, A., & Rötig, A. (1995) · Nature Genetics · doi:10.1038/ng1095-144 · Cited by 730
PURIFICATION OF AMINE OXIDASE FROM BEEF PLASMA
Tabor, C. W., Tabor, H., & Rosenthal, S. M. (1954) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)65591-7 · Cited by 725

Show all 41 references

Research works printed but not linked: 1

Tabor CW, 1954, Amine oxidases, J Biol Chem, 208, 645

Sorted by citations

Items 101–200 of 883

Mitochondria, energy, and metabolism in neuronal health and disease
Trigo, D., Avelar, C., Fernandes, M., Sá, J., & Silva, O. A. B. D. C. E. (2022) · FEBS Letters · doi:10.1002/1873-3468.14298 · Cited by 225
Mitochondrial calcium function and dysfunction in the central nervous system
Nicholls, D. G. (2009) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2009.03.010 · Cited by 213
trans-(−)-ε-Viniferin Increases Mitochondrial Sirtuin 3 (SIRT3), Activates AMP-activated Protein Kinase (AMPK), and Protects Cells in Models of Huntington Disease
Fu, J., Jin, J., Cichewicz, R. H., Hageman, S. A., Ellis, T. K., Xiang, L., Peng, Q., Jiang, M., Arbez, N., Hotaling, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.382226 · Cited by 213
Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex
Polidori, M. C., Mecocci, P., Browne, S. E., Senin, U., & Beal, M. F. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00578-9 · Cited by 211
Self-citation
Mitochondrial dysfunction in neurodegenerative disorders
Schapira, A. H. V. (1998) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/s0005-2728(98)00115-7 · Cited by 213
Mitochondrial dysfunction, oxidative stress and neurodegeneration
Mancuso, M., Coppedè, F., Migliore, L., Siciliano, G., & Murri, L. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-10110 · Cited by 212
The biological function of the Huntingtin protein and its relevance to Huntington's Disease pathology.
Schulte, J., & Littleton, J. T. (2011) · PubMed · Cited by 203
Curcumin nanoparticles attenuate neurochemical and neurobehavioral deficits in experimental model of huntington’s disease.
Sandhir, R., Yadav, A., Mehrotra, A., Sunkaria, A., Singh, A., & Sharma, S. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8261-y · Cited by 204
Mitochondria in Neurodegeneration
Lezi, E., & Swerdlow, R. H. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-94-007-2869-1_12 · Cited by 213
Thalamic metabolism and symptom onset in preclinical Huntington's disease
Feigin, A., Tang, C., Ma, Y., Mattis, P. J., Zgaljardic, D. J., Guttman, M., Paulsen, J. S., DHAWAN, V. M., & Eidelberg, D. (2007) · Brain · doi:10.1093/brain/awm217 · Cited by 198
Mutant HTT (huntingtin) impairs mitophagy in a cellular model of Huntington disease
Franco-Iborra, S., Plaza‐Zabala, A., Montpeyó, M., Sebastián, D., Vila, M., & Martínez‐Vicente, M. (2020) · Autophagy · doi:10.1080/15548627.2020.1728096 · Cited by 205
Early Degenerative Changes in Transgenic Mice Expressing Mutant Huntingtin Involve Dendritic Abnormalities but No Impairment of Mitochondrial Energy Production
Guidetti, P., Charles, V., Chen, E., Reddy, P. H., Kordower, J. H., Whetsell, W. O., Schwarcz, R. M., & Tagle, D. A. (2001) · Experimental Neurology · doi:10.1006/exnr.2000.7626 · Cited by 197
Neuronal cell death in Huntington’s disease: a potential role for dopamine
Jakel, R. J., & Maragos, W. F. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01568-x · Cited by 199
Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects
Leonard, J. V., & Schapira, A. H. V. (2000) · The Lancet · doi:10.1016/s0140-6736(99)05226-5 · Cited by 197
Apoptosis in Huntington's disease
Hickey, M. A., & Chesselet, M.-F. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(03)00021-6 · Cited by 199
Mitochondrial Quality Control in Neurodegenerative Diseases: Focus on Parkinson's Disease and Huntington's Disease
Franco-Iborra, S., Vila, M., & Perier, C. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00342 · Cited by 197
Calcium Homeostasis and Mitochondrial Dysfunction in Striatal Neurons of Huntington Disease
Lim, D., Fedrizzi, L., Tartari, M., Zuccato, C., Cattaneo, E. F., Brini, M., & Carafoli, E. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704704200 · Cited by 194
Cellular Localization of Huntingtin in Striatal and Cortical Neurons in Rats: Lack of Correlation with Neuronal Vulnerability in Huntington’s Disease
Fusco, F. R., Chen, Q., L’Amoreaux, W. J., Figueredo-Cardenas, G., Jiao, Y., Coffman, J. A., Surmeier, D. J., Honig, M. G., Carlock, L. R., & Reiner, A. J. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-04-01189.1999 · Cited by 192
Generalized brain and skin proteasome inhibition in Huntington’s disease
Seo, H., Sonntag, K., & Isacson, O. (2004) · Annals of Neurology · doi:10.1002/ana.20207 · Cited by 188
Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington's disease
Reddy, P. H., & Shirendeb, U. P. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.016 · Cited by 188
A review of the mechanisms of cone degeneration in retinitis pigmentosa
Narayan, D. S., Wood, J. P. M., Chidlow, G., & Casson, R. J. (2016) · Acta Ophthalmologica · doi:10.1111/aos.13141 · Cited by 196
Neuroprotective effects of creatine
Beal, M. F. (2011) · Amino Acids · doi:10.1007/s00726-011-0851-0 · Cited by 196
Self-citation
Mitochondrial DNA damage and repair in neurodegenerative disorders
Yang, J., Weissman, L., Bohr, V. A., & Mattson, M. P. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.03.012 · Cited by 187
Safety of Intrastriatal Neurotransplantation for Huntington's Disease Patients
Kopyov, O. V., Jacques, S., LIEBERMAN, A. N., Duma, C., & Eagle, K. S. (1998) · Experimental Neurology · doi:10.1006/exnr.1997.6685 · Cited by 186
Proteomic Analysis of Protein Expression and Oxidative Modification in R6/2 Transgenic Mice
Marzia Perluigi, A., Poon, H. F., Maragos, W. F., Pierce, W. M. J., Klein, J. B., Calabrese, V., Cini, C., Marco, C. M. D., & Butterfield, D. A. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m500090-mcp200 · Cited by 184
Increased basal ganglia iron levels in Huntington disease
Bartzokis, G., Cummings, J., Perlman, S., Hance, D. B., & Mintz, J. (1999) · Archives of Neurology · doi:10.1001/archneur.56.5.569 · Cited by 183
Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles
Underwood, B. R., Broadhurst, D., Dunn, W. B., Ellis, D. I., Michell, A. W., Vacher, C., Mosedale, D. E., Kell, D. B., Barker, R. A., Grainger, D. J., et al. (2006) · Brain · doi:10.1093/brain/awl027 · Cited by 184
Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease
Carsten Saft, C., Zange, J., Andrich, J., Müller, K., Lindenberg, K. S., Landwehrmeyer, G. B., Vorgerd, M., Kraus, P. H., Przuntek, H., & Schöls, L. J. (2005) · Movement Disorders · doi:10.1002/mds.20373 · Cited by 184
Protein Oxidation in Aging: Does It Play a Role in Aging Progression?
Reeg, S., & Grune, T. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6062 · Cited by 191
Increased Formation of Reactive Oxygen Species, but No Changes in Glutathione Peroxidase Activity, in Striata of Mice Transgenic for the Huntington's Disease Mutation
Pérez‐Severiano, F., Santamarı́a, A., Pedraza‐Chaverrí, J., Medina‐Campos, O. N., Rı́os, C., & Segovia, J. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000018843.83770.4b · Cited by 181
The role of mitochondria in inherited neurodegenerative diseases
Kwong, J. Q., Beal, M. F., & Manfredi, G. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03990.x · Cited by 180
Self-citation
Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases
Adhihetty, P. J., & Beal, M. F. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8053-y · Cited by 190
Self-citation
A carbon column-based liquid chromatography electrochemical approach to routine 8-hydroxy-2′-deoxyguanosine measurements in urine and other biologic matrices: a one-year evaluation of methods
Bogdanov, M. B., Beal, M. F., McCabe, D. R., Griffin, R. M., & Matson, W. R. (1999) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(99)00113-6 · Cited by 179
Self-citation
Mitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models
Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176
Self-citation
Cystamine Inhibits Caspase Activity
Lesort, M. J., Lee, M., Tucholski, J., & Johnson, G. V. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m205812200 · Cited by 177
Increased Susceptibility of Striatal Mitochondria to Calcium-Induced Permeability Transition
Brustovetsky, N., Brustovetsky, T., Purl, K. J., Capano, M., Crompton, M., & Dubinsky, J. M. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-04858.2003 · Cited by 179
Antioxidant gene therapy against neuronal cell death
Navarro-Yepes, J., Zavala-Flores, L. M., Anandhan, A., Wang, F., Skotak, M., Chandra, N., Li, M., Pappa, A., Martínez‐Fong, D., Razo, L. M. D., et al. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.12.007 · Cited by 182
Selective defect of in vivo glycolysis in early Huntington's disease striatum
Powers, W. J., Videen, T. O., Markham, J., McGee‐Minnich, L., Antenor‐Dorsey, J. A. V., Hershey, T. G., & Perlmutter, J. S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609833104 · Cited by 174
Synaptic pathology: A shared mechanism in neurological disease
Henstridge, C. M., Pickett, E. K., & Spires‐Jones, T. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.04.005 · Cited by 176
Role of mitochondrial dysfunction in the pathogenesis of Huntington's disease
Quintanilla, R. A., & Johnson, G. V. W. (2009) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2009.07.010 · Cited by 176
Tissue transglutaminase: a possible role in neurodegenerative diseases
Lesort, M. J., Tucholski, J., Miller, M. L., & Johnson, G. V. W. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00052-0 · Cited by 173
Differential vulnerability of neurons in Huntington’s disease: the role of cell type‐specific features
Han, I., You, Y., Kordower, J. H., Brady, S. T., & Morfini, G. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06672.x · Cited by 176
Complex I Defect in muscle from patients with Huntington's disease
Arenas, J., Campos, Y., Ribacoba, R., Martín, M. A., Rubio‐Terres, C., Ablanedo, P., & Cabello, A. (1998) · Annals of Neurology · doi:10.1002/ana.410430321 · Cited by 174
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease
Stack, C., Ho, D. J., Wille, E. J., Calingasan, N. Y., Williams, C. R., Liby, K. T., Sporn, M. B., Dumont, M., & Beal, M. F. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.03.017 · Cited by 175
Self-citation
The selective vulnerability of striatopallidal neurons
Mitchell, I., Cooper, A. J., & Griffiths, M. (1999) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00019-2 · Cited by 170
Evidence of Oxidant Damage in Huntington's Disease: Translational Strategies Using Antioxidants
Stack, E. C., Matson, W. R., & Ferrante, R. J. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.008 · Cited by 169
Redox Proteomics in Selected Neurodegenerative Disorders: From Its Infancy to Future Applications
Butterfield, D. A., Marzia Perluigi, A., Reed, T. T., Muharib, T., Hughes, C. P., Robinson, R. A. S., & Rukhsana Sultana, A. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4109 · Cited by 171
Huntington disease: A single-gene degenerative disorder of the striatum
Nopoulos, P. C. (2016) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2016.18.1/pnopoulos · Cited by 161
Huntington's Disease and the Striatal Medium Spiny Neuron: Cell-Autonomous and Non-Cell-Autonomous Mechanisms of Disease
Ehrlich, M. E. (2012) · Neurotherapeutics · doi:10.1007/s13311-012-0112-2 · Cited by 170
Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases
Gubellini, P., Pisani, A., Centonze, D., Bernardi, G., & Calabresi, P. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.09.005 · Cited by 170
Calpain Is a Major Cell Death Effector in Selective Striatal Degeneration InducedIn Vivoby 3-Nitropropionate: Implications for Huntington's Disease
Bizat, N., Hermel, J., Boyer, F., Jacquard, C., Créminon, C., Ouary, S., Escartin, C., Hantraye, P., Krajewski, S., & Brouillet, E. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-12-05020.2003 · Cited by 163
Nature and cause of mitochondrial dysfunction in Huntington’s disease: focusing on huntingtin and the striatum
Oliveira, J. M. A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06741.x · Cited by 163
Selective Neuronal Degeneration in Huntington's Disease
Cowan, C. M., & Raymond, L. A. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(06)75002-5 · Cited by 166
Inhibition of Mitochondrial Complex II Induces a Long-Term Potentiation of NMDA-Mediated Synaptic Excitation in the Striatum Requiring Endogenous Dopamine
Calabresi, P., Gubellini, P., Picconi, B., Centonze, D., Pisani, A., Bonsi, P., Greengard, P., Hipskind, R. A., Borrelli, E., & Bernardi, G. (2001) · Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05110.2001 · Cited by 163
Shaping the role of mitochondria in the pathogenesis of Huntington's disease
Costa, V., & Scorrano, L. (2012) · The EMBO Journal · doi:10.1038/emboj.2012.65 · Cited by 162
Brain metabolism and brain disease: Is metabolic deficiency the proximate cause of Alzheimer dementia?
Blass, J. P. (2001) · Journal of Neuroscience Research · doi:10.1002/jnr.10087 · Cited by 165
Mitochondrial structural and functional dynamics in Huntington's disease
Reddy, P. H., Mao, P., & Mańczak, M. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.04.001 · Cited by 164
Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease
Johri, A., Calingasan, N. Y., Hennessey, T., Sharma, A., Yang, L., Wille, E. J., Chandra, A., & Beal, M. F. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr541 · Cited by 163
Self-citation
Huntingtin-deficient zebrafish exhibit defects in iron utilization and development
Lumsden, A. L., Henshall, T. L., Dayan, S., Lardelli, M. T., & Richards, R. I. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm138 · Cited by 156
Reactive oxygen species-responsive drug delivery systems for the treatment of neurodegenerative diseases
Ballance, W. C., Qin, E. C., Chung, H. J., Gillette, M. U., & Kong, H. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119292 · Cited by 156
Transglutaminases in disease
Kim, S., Jeitner, T. M., & Steinert, P. M. (2002) · Neurochemistry International · doi:10.1016/s0197-0186(01)00064-x · Cited by 156
Efficacy of Fumaric Acid Esters in the R6/2 and YAC128 Models of Huntington's Disease
Ellrichmann, G., Petrasch‐Parwez, E., Lee, D.-H., Reick, C., Arning, L., Carsten Saft, C., Gold, R., & Linker, R. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016172 · Cited by 155
Itaconate modulates tricarboxylic acid and redox metabolism to mitigate reperfusion injury
Cordes, T., Lucas, A., Divakaruni, A. S., Murphy, A. N., Cabrales, P., & Metallo, C. M. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.11.019 · Cited by 156
Mitochondria and the Link Between Neuroinflammation and Neurodegeneration
Filippo, M. D., Chiasserini, D., Tozzi, A., Picconi, B., & Calabresi, P. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100543 · Cited by 158
Coenzyme Q10 and remacemide hydrochloride ameliorate motor deficits in a Huntington's disease transgenic mouse model
Schilling, G., Coonfield, M. L., Ross, C. A., & Borchelt, D. R. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(01)02326-6 · Cited by 151
Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders
Mena, N. P., Urrutia, P. J., Lourido, F., Carrasco, C. M., & Núñez, M. T. (2015) · Mitochondrion · doi:10.1016/j.mito.2015.02.001 · Cited by 154
Mitochondrial DNA damage Is associated with reduced mitochondrial bioenergetics in Huntington's disease
Siddiqui, A., Rivera, S., Castro, M. D. R., Acevedo‐Torres, K., Rane, A., Torres‐Ramos, C. A., Nicholls, D. G., Andersen, J. K., & Ayala‐Torres, S. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.06.008 · Cited by 154
Therapeutics development for triplet repeat expansion diseases
Prospero, N. A. D., & Fischbeck, K. H. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1690 · Cited by 149
Polyglutamine Diseases: Where does Toxicity Come from? What is Toxicity? Where are We Going?
Takahashi, T., Katada, S., & Onodera, O. (2010) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjq005 · Cited by 157
Lycopene prevents 3-nitropropionic acid-induced mitochondrial oxidative stress and dysfunctions in nervous system
Sandhir, R., Mehrotra, A., & Kamboj, S. S. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.07.005 · Cited by 149
Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease
McConoughey, S. J., Basso, M., Niatsetskaya, Z. V., Sleiman, S. F., Smirnova, N. A., Langley, B. C., Mahishi, L., Cooper, A. J. L., Antonyak, M. A., Cerione, R. A., et al. (2010) · EMBO Molecular Medicine · doi:10.1002/emmm.201000084 · Cited by 146
Self-citation
Role of oxidative DNA damage in mitochondrial dysfunction and Huntington’s disease pathogenesis
Ayala‐Peña, S. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.04.017 · Cited by 147
Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease
Yin, X., Mańczak, M., & Reddy, P. H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw045 · Cited by 144
Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities
Sbodio, J. I., Snyder, S. H., & Paul, B. D. (2018) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7321 · Cited by 149
Reduction of glyceraldehyde‐3‐phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts
Mazzola, J. L., & Sirover, M. A. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00033.x · Cited by 143
Mechanisms of protein toxicity in neurodegenerative diseases
Chung, C. G., Lee, H., & Lee, S. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2854-4 · Cited by 142
Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders
Covarrubias‐Pinto, A., Acuña, A. I., Beltrán, F. A., Torres-Díaz, L., & Castro, M. A. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms161226095 · Cited by 140
Mutant Huntingtin Expression Induces Mitochondrial Calcium Handling Defects in Clonal Striatal Cells
Milakovic, T., Quintanilla, R. A., & Johnson, G. V. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m603845200 · Cited by 142
Mitochondria and Neurodegeneration
Petrozzi, L., Ricci, G., Giglioli, N. J., Siciliano, G., & Mancuso, M. (2007) · Bioscience Reports · doi:10.1007/s10540-007-9038-z · Cited by 139
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
McGarry, A. J., McDermott, M., Kieburtz, K. D., de Blieck, E. A., Beal, F. M., Marder, K. S., Ross, C. A., Shoulson, I., Gilbert, P. R., Mallonee, W. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003478 · Cited by 139
Insulin and IGF-1 improve mitochondrial function in a PI-3K/Akt-dependent manner and reduce mitochondrial generation of reactive oxygen species in Huntington’s disease knock-in striatal cells
Ribeiro, M., Rosenstock, T. R., Oliveira, A. M., Oliveira, C. R., & Rego, A. C. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.06.023 · Cited by 145
Mitochondria targeted therapeutic approaches in Parkinson's and Huntington's diseases
Chaturvedi, R. K., & Beal, M. F. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.11.011 · Cited by 139
Self-citation
Intracellular Sources of ROS/H2O2 in Health and Neurodegeneration: Spotlight on Endoplasmic Reticulum
Konno, T., Melo, E. P., Chambers, J. E., & Avezov, E. (2021) · Cells · doi:10.3390/cells10020233 · Cited by 143
Oxidative damage to DNA in plaques of MS brains
Vladimirova, O. V., O'Connor, J. J., Cahill, A., Alder, H., Butunoi, C., & Kálmán, B. (1998) · Multiple Sclerosis Journal · doi:10.1177/135245859800400503 · Cited by 138
Cytotoxicity of a mutant huntingtin fragment in yeast involves early alterations in mitochondrial OXPHOS complexes II and III
Solans, A., Zambrano, A., Rodríguez, M., & Barrientos, A. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl248 · Cited by 142
N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease
Wright, D. J., Renoir, T., Smith, Z. M., Frazier, A. E., Francis, P. S., Thorburn, D. R., McGee, S. L., Hannan, A. J., & Gray, L. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2014.131 · Cited by 137
Metabolic Dysfunction in Familial, but Not Sporadic, Amyotrophic Lateral Sclerosis
Browne, S. E., Bowling, A. C., Baik, M. J., Gurney, M. E., Brown, R. H., & Beal, M. F. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71010281.x · Cited by 136
Self-citation
Proteasome Activator Enhances Survival of Huntington's Disease Neuronal Model Cells
Seo, H., Sonntag, K., Kim, W., Cattaneo, E. F., & Ole Isacson, A. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000238 · Cited by 133
Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease
Mihm, M. J., Amann, D. M., Schanbacher, B. L., Altschuld, R. A., Bauer, J. A., & Hoyt, K. R. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.09.016 · Cited by 136
Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation
Chaturvedi, R. K., Calingasan, N. Y., Yang, L., Hennessey, T., Johri, A., & Beal, M. F. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq229 · Cited by 140
Self-citation
Striatal spiny neurons and cholinergic interneurons express differential ionotropic glutamatergic responses and vulnerability: Implications for ischemia and Huntington's disease
Calabresi, P., Centonze, D., Pisani, A., Sancesario, G., Gubellini, P., Marfia, G. A., & Bernardi, G. (1998) · Annals of Neurology · doi:10.1002/ana.410430506 · Cited by 133
A Bile Acid Protects against Motor and Cognitive Deficits and Reduces Striatal Degeneration in the 3-Nitropropionic Acid Model of Huntington's Disease
Keene, C. D., Rodrigues, C. M. P., Eich, T., Linehan-Stieers, C., Abt, A., Kren, B. T., Steer, C. J., & Low, W. C. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7755 · Cited by 132
Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases
Shadfar, S., Parakh, S., Jamali, M. S., & Atkin, J. D. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00350-4 · Cited by 148
Mechanisms of DNA damage-mediated neurotoxicity in neurodegenerative disease
Welch, G., & Tsai, L. (2022) · The EMBO Reports · doi:10.15252/embr.202154217 · Cited by 129
Creatine supplementation lowers brain glutamate levels in Huntington?s disease
Bender, A., Auer, D. P., Merl, T., Reilmann, R., Saemann, P., Yassouridis, A., Bender, J., Weindl, A., Dose, M., Gasser, T., et al. (2005) · Journal of Neurology · doi:10.1007/s00415-005-0595-4 · Cited by 129
Nuclear and cytoplasmic huntingtin inclusions exhibit distinct biochemical composition, interactome and ultrastructural properties
Riguet, N., Mahul-Mellier, A.-L., Maharjan, N., Burtscher, J., Croisier, M., Knott, G., Hastings, J., Patin, A., Reiterer, V., Farhan, H., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26684-z · Cited by 118
Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease
Acevedo‐Torres, K., Berríos, L., Rosario, N., Dufault, V. M., Skatchkov, S. N., Eaton, M. J., Torres‐Ramos, C. A., & Ayala‐Torres, S. (2008) · DNA repair · doi:10.1016/j.dnarep.2008.09.004 · Cited by 126
A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin
Damiano, M. G., Diguet, E., Malgorn, C., D’Aurelio, M., Galvan, L., Petit, F., Haim, L. B., Guillermier, M., Houitte, D., Dufour, N., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt242 · Cited by 124
Self-citation
The α‐Ketoglutarate Dehydrogenase Complex
Sheu, K. R., & Blass, J. P. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07818.x · Cited by 125
In Vivo Calpain/Caspase Cross-talk during 3-Nitropropionic Acid-induced Striatal Degeneration
Bizat, N., Hermel, J., Humbert, S., Jacquard, C., Créminon, C., Escartin, C., Saudou, F., Krajewski, S., Hantraye, P., & Brouillet, E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305057200 · Cited by 125

Authors: Browne, S. E., Bowling, A. C., Macgarvey, U., Baik, M. J., Berger, S. C., Muquit, M. M. K., Bird, E. D., & Beal, M. F.
Affiliations: Harvard University (US)
McLean Hospital (US)
Corresponding author: Beal, M. Flint
ORCID: Browne, Susan E.
Beal, M. Flint
Venue: Annals of Neurology
Publisher: Wiley
Published: 1997-05
Volume: 41
Issue: 5
Pages: 646-653
ISSN: 0364-5134 (ISSN-L)
1531-8249
DOI: 10.1002/ana.410410514
OpenAlex: W2102430316
Cited by: 885
References: 41
Citations by year: 2026: 14 · 2025: 12 · 2024: 18 · 2023: 17 · 2022: 25 · 2021: 33 · 2020: 22 · 2019: 18 · 2018: 31 · 2017: 13 · 2016: 47 · 2015: 31 · 2014: 41 · 2013: 37 · 2012: 46
FWCI: 10.37
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 2717 d)
Locations: Annals of Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Keywords: Huntington's disease, oxidative damage, metabolic dysfunction, basal ganglia, selective neuronal vulnerability, oxidative phosphorylation, complex IV activity, complex I, glyceraldehyde-3-phosphate dehydrogenase, huntingtin, 8-hydroxy-2'-deoxyguanosine, superoxide dismutase, caudate nucleus, putamen, postmortem brain
MeSH terms: Basal Ganglia, Cerebellum, Cerebral Cortex, DNA, Glyceraldehyde-3-Phosphate Dehydrogenases, Humans, Huntington Disease, Mitochondria, Oxidation-Reduction, Reference Values, Spectrophotometry, Stress, Physiological, Superoxide Dismutase, NAD(P)H Dehydrogenase (Quinone), In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks